Actelion’s pulmonary arterial hypertension drug macitentan has met its primary endpoint in a Phase III trial. The news comes after …
Swiss biotech firm Actelion is mounting a defence of its management board and strategy following an offensive by a shareholder …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations

